Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
NEJM 2024
MHRA-licensed options include semaglutide (Wegovy), liraglutide (Saxenda), orlistat, and tirzepatide (Mounjaro)
Heres a quick look at how they stack up: So, while L-Citrulline keeps it simple, Citrulline Malate brings a little extra to the party
US$ 26.30
US$ 26.52
US$ 23.00
US$ 29.32
US$ 26.71
US$ 25.48
US$ 21.89
